about
Upregulation of meiosis-specific genes in lymphoma cell lines following genotoxic insult and induction of mitotic catastropheThe "virgin birth", polyploidy, and the origin of cancerThe biology of CD20 and its potential as a target for mAb therapyGefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimeticsNovel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.The potential effect of statins on rituximab immunotherapy.Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal.PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosisPolyploid giant cells provide a survival mechanism for p53 mutant cells after DNA damage.Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also BimSegregation of genomes in polyploid tumour cells following mitotic catastrophe.Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?Coupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia in the Adult BrainConformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.Fcγ receptor-mediated inflammation inhibits axon regeneration.Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domainEvaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus.Mitotic catastrophe and endomitosis in tumour cells: an evolutionary key to a molecular solution.BCR-signaling-induced cell death demonstrates dependency on multiple BH3-only proteins in a murine model of B-cell lymphoma.Transforming growth factor-β directly induces p53-up-regulated modulator of apoptosis (PUMA) during the rapid induction of apoptosis in myc-driven B-cell lymphomas.Role of stress-activated OCT4A in the cell fate decisions of embryonal carcinoma cells treated with etoposide.Mechanisms of killing by anti-CD20 monoclonal antibodies.Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.Cancer: a matter of life cycle?The European antibody network's practical guide to finding and validating suitable antibodies for research.Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics.CD20 as a target for therapeutic type I and II monoclonal antibodies.B cells--masters of the immunoverse.FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.Novel antibodies targeting immune regulatory checkpoints for cancer therapy.FcγRIIB as a key determinant of agonistic antibody efficacy.Fcγ receptors: genetic variation, function, and disease.FcγR requirements leading to successful immunotherapy.Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy.Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB.Anti-FcγRIIB (CD32) Antibodies Differentially Modulate Murine FVIII-Specific Recall Response in vitro.FcγRIIB-Independent Mechanisms Controlling Membrane Localization of the Inhibitory Phosphatase SHIP in Human B Cells.Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors.
P50
Q24539125-468B192A-4A2C-42C4-8AE0-4478B13F9D01Q27024916-307FA718-EB86-48D5-B719-2DCE0A8CC78FQ28295215-4A2F728B-FBC1-4267-8821-76B424CE24EDQ28469345-508D3F5E-5054-4FFE-A70F-5A4987892EF8Q30500362-504DD512-591C-4E6C-A0FE-E41F3D631237Q33325581-448591BB-1C62-47D1-8D6F-E510DA2F2B2CQ33590178-E91EA07C-20A5-4169-A7EC-6C2EB12C2285Q33785941-0CD4B3EE-2F88-40E7-926C-C2ADF4BBA3F9Q33915750-EAE1B99A-C504-4858-A42F-35FF9EC15C5AQ34450473-647C6631-1570-4857-AEBA-16756C502EEAQ34470954-D68F2B57-6562-443E-80AA-CFC6262FEE85Q34532006-00CE9890-8ADD-477F-AA2A-F5C43452544DQ34680501-61C842E0-819B-4F10-8CDD-9E50D5A281ECQ34978570-0B864022-1F3A-46B6-A0F5-5EC2F869981CQ35075545-0120932C-057F-45F6-A1C9-F86FDEF34EF6Q35093733-D35D6938-10B5-4F80-A888-03ADB156DA4AQ35126604-C9590B56-3FD0-4442-B0D6-D05148263B87Q35834551-87CC189C-954F-4434-A36C-22D4A6BE7782Q36323376-6E139D9E-A973-4403-8417-77B50551754CQ36472505-D31A202D-CFAF-40AD-B7AC-193CA2198BF3Q36620902-DAD300FE-3394-44D1-940A-8BA820F7CE1BQ36780731-70538A96-DA60-47C5-AC2C-D2534F2C583FQ36927853-02CF3FCD-6053-4052-B599-11BBE0618FA6Q36945203-7C241A3A-7490-4720-A95D-F22DE4870183Q36971307-2E30C156-1088-41E7-B113-8921050E6356Q37138282-98DF3774-98A4-4BB0-810B-ACA78F9A763BQ37255665-F6074C0E-37C3-4D1C-8D80-8D5BCB2662A6Q37431491-C8CD0B8E-2A65-4B85-AEF2-A856D2BB1F4CQ37720878-926AAEE0-993F-4CFA-9C99-261746B2A918Q37819339-1BE565D5-12EC-45A1-954D-2BCCBB6F6038Q38094625-58923C44-7FF3-4CB4-AB12-1FA165B90CF8Q38108836-AC78B843-B9AE-4905-B34A-E88C3359D7ACQ38239285-C0D7A39F-EA13-4C2C-9AB5-AA3DE7B64F8BQ38615347-4EB7BC7A-973D-4CED-9D25-384B260CD06BQ38615360-4128BC8D-33BA-4EE7-A3AD-882958BE7AA3Q38736915-8F77879B-8206-4DD8-9ED1-38D52C91A529Q38752906-CA31D456-7149-48F7-9A4D-A2C93C94A78FQ38754659-FF2176A5-FA71-475E-B9A6-DA376570EAEFQ38755941-587FF74E-E72C-4C89-9C79-B648EE52925EQ38824031-75C07373-5999-47F6-953C-46C657A96205
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mark S Cragg
@ast
Mark S Cragg
@en
Mark S Cragg
@es
Mark S Cragg
@nl
Mark S Cragg
@sl
type
label
Mark S Cragg
@ast
Mark S Cragg
@en
Mark S Cragg
@es
Mark S Cragg
@nl
Mark S Cragg
@sl
prefLabel
Mark S Cragg
@ast
Mark S Cragg
@en
Mark S Cragg
@es
Mark S Cragg
@nl
Mark S Cragg
@sl
P106
P21
P2798
P31
P3835
mark-cragg
P496
0000-0003-2077-089X